Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Interested in new trials?
Get alerts for new trials in your area by subscribing now
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
What is C. diff?
C. diff is an infection of the large intestine caused by Clostridioides difficile, a spore forming bacterium that produces toxins that damage the bowel lining. It causes watery diarrhea, abdominal cramping, fever, and nausea, and in severe cases a dangerous swelling of the colon. The biggest risk factor is recent antibiotic use, which clears the normal gut bacteria that keep C. diff in check; being over 65, a recent hospital or nursing home stay, a weakened immune system, and acid suppressing medicines also raise risk. The spores spread easily on hands and surfaces, which is why C. diff is a leading hospital acquired infection.
Treatment is an antibiotic that targets C. diff itself, most often fidaxomicin or vancomycin, with fidaxomicin now preferred because fewer people relapse after it. Recurrence is the central problem, and for people whose infection keeps coming back, two microbiota based products approved in 2022 and 2023 restore healthy gut bacteria, one given rectally and the first taken as capsules. Bowel inflammation from other causes is covered on our ulcerative colitis and IBS pages.
New to research? Read how placebo controlled trials work.
Types of C. diff clinical trials
Recurrence prevention trials. Microbiome restoration products, antibodies against C. diff toxins, and strategies that compare treatments head to head in people who have relapsed.
New antibiotic trials. Narrow spectrum drugs designed to kill C. diff while sparing the rest of the gut bacteria.
Vaccine trials. Vaccines aimed at the toxins C. diff produces, tested in older adults and people at high risk; none is approved yet.
Hospital prevention studies. Screening, isolation, cleaning, and antibiotic stewardship programs that reduce infections in hospitals and nursing homes.
Severe infection trials. Treatments and surgery decisions for fulminant C. diff, the most dangerous form.
Microbiome research. Studies of how gut bacteria protect against infection, sometimes enrolling healthy volunteers as donors or comparison groups.
Who can participate in C. diff clinical trials?
Treatment trials usually enroll adults with a C. diff infection confirmed by a stool test, often within days of diagnosis, and specify whether it is a first episode or a recurrence; recurrence prevention trials require one or more prior episodes. Vaccine trials enroll people at risk, such as adults over 50 or 65 with a planned hospital stay or recent antibiotics, who do not currently have the infection. Many trials exclude people with inflammatory bowel disease flares or those who cannot take oral medicine. Hospital prevention studies enroll whole units or facilities rather than individual volunteers. Eligibility always varies by study.
Types of C. diff infection, and why they matter for trials
First episode. Treated with fidaxomicin or vancomycin; trials test new antibiotics and ways to reduce the chance of relapse from the start.
Recurrent infection. One or more episodes after treatment; the target of microbiome products, antibody treatments, and most prevention trials.
Severe or fulminant infection. Very low blood pressure, severe colon swelling, or kidney effects; treated in hospital, with trials on treatment and surgery timing.
At risk, not infected. People facing antibiotics or hospital stays; the group vaccine and prevention trials enroll.
Is there a vaccine for C. diff?
Not yet. Vaccines aimed at C. diff toxins have been tested in large trials, and research continues, but none is approved. Vaccine studies enroll people at risk rather than people who are currently infected.
Do C. diff trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in a C. diff clinical trial
Identify your trial. Use the filters and search "C. diff," "Clostridioides difficile," and "CDI," since listings use all three.
Select your preferred location. Enter your city or state; treatment trials run at hospitals and infectious disease clinics, prevention studies more widely.
Explore study details. Click "Learn More" for whether the study enrolls first or recurrent infections, timing from diagnosis, and current antibiotic rules.
Complete the health profile. Click "Get started" to begin the 5-step application. Have ready the date of your diagnosis, how many episodes you have had, and the antibiotics you have taken recently.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.